Screener
BridgeBio Pharma BBIO Reportable Segment — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Encaleret for ADH1 | 20,428 | 15,459 |
| Other development programs | 6,760 | 11,430 |
| Other research programs | 16,916 | 18,007 |
| Total segment research and development | 126,636 | 111,431 |
| Selling, general and administrative | 163,896 | 106,365 |
| Restructuring, impairment, and related charges | — | 570 |
| Total operating costs and expenses | 300,471 | 221,005 |
| Loss from operations | (105,956) | (104,372) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's reportable segment — R&D?
- BridgeBio Pharma (BBIO) reported reportable segment — R&D of $126.64M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — R&D changed year-over-year?
- BridgeBio Pharma's reportable segment — R&D increased by 13.6% year-over-year, from $111.43M to $126.64M.
- What does reportable segment — R&D mean?
- Captures the expenditures dedicated to the discovery, clinical trials, and development of new therapeutic candidates within the segment. This is a critical investment for long-term pipeline viability.
Ask your AI about BridgeBio Pharma's reportable segment — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude